Drug Information

Drug General Information
Drug ID
D06ABW
Former ID
DNC011356
Drug Name
CLIOQUINOL
Drug Type
Small molecular drug
Indication Discovery agent Withdrawn from market [522766]
Formula
C9H5ClINO
Canonical SMILES
C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1
InChI
1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
InChIKey
QCDFBFJGMNKBDO-UHFFFAOYSA-N
CAS Number
CAS 130-26-7
PubChem Compound ID
2788
SuperDrug ATC ID
D08AH30; D09AA10; G01AC02; P01AA02; S02AA05
Target and Pathway
Target(s) Carbonic anhydrase Target Info Inhibitor [529489]
Kappa-type opioid receptor Target Info Inhibitor [531262]
KEGG Pathway Neuroactive ligand-receptor interaction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Opioid prodynorphin pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 522766ClinicalTrials.gov (NCT00963495) Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy. U.S. National Institutes of Health.
Ref 529489Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. Epub 2008 May 4.Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
Ref 531262Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.